Compass Pathways’ (CMPS) Overweight Rating Reiterated at Morgan Stanley

by · The Markets Daily

Compass Pathways (NASDAQ:CMPS – Get Free Report)‘s stock had its “overweight” rating restated by investment analysts at Morgan Stanley in a research report issued on Tuesday,Benzinga reports. They presently have a $17.00 target price on the stock. Morgan Stanley’s target price would indicate a potential upside of 31.94% from the stock’s current price.

Several other brokerages have also recently weighed in on CMPS. UBS Group set a $18.00 target price on Compass Pathways in a report on Thursday, May 7th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Tuesday. TD Cowen reiterated a “buy” rating on shares of Compass Pathways in a report on Monday, June 1st. BTIG Research boosted their price target on shares of Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $24.73.

Read Our Latest Stock Report on CMPS

Compass Pathways Trading Up 0.4%

Shares of Compass Pathways stock traded up $0.04 on Tuesday, reaching $12.88. The company had a trading volume of 12,320,503 shares, compared to its average volume of 3,697,287. The firm’s 50-day moving average price is $11.63 and its two-hundred day moving average price is $8.43. Compass Pathways has a 1 year low of $3.34 and a 1 year high of $15.40. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -4.09 and a beta of 2.47. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32.

Compass Pathways (NASDAQ:CMPS – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. As a group, research analysts predict that Compass Pathways will post -1.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Pathways

Several hedge funds have recently modified their holdings of CMPS. EverSource Wealth Advisors LLC raised its holdings in shares of Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in Compass Pathways during the 4th quarter worth about $38,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Compass Pathways during the 4th quarter valued at about $47,000. Advisory Services Network LLC purchased a new position in shares of Compass Pathways during the 3rd quarter valued at about $41,000. Finally, Parallel Advisors LLC lifted its holdings in shares of Compass Pathways by 8,450.6% in the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

About Compass Pathways

(Get Free Report)

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

See Also